Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Common drug may shield kidneys from chemo harm

NCT ID NCT05640817

Symptom relief Sponsor: Tanta University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether pentoxifylline, a drug used for blood flow problems, can protect the kidneys from damage caused by cisplatin chemotherapy in head and neck cancer patients. 90 adults receiving cisplatin for the first time took part. Researchers measured kidney injury using standard tests and a specific marker called KIM-1.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pentoxifylline
What this could lead to
If it works, this could offer a simple way to reduce kidney damage from cisplatin chemotherapy, helping patients complete their cancer treatment with fewer side effects.
What could go wrong
This is a small, completed study without a phase designation, so results may not be definitive. Pentoxifylline may not provide meaningful protection for all patients, and its benefits need confirmation in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

90 people

The number who actually took part.

Started

Jan 2023

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: 1. Patient aged 18 years or more with head and neck cancer who will receive cisplatin for the first time. 2. Baseline estimated glomerular filtration rate (eGFR) ≥ 59 ml/min/1.73 m2. 3. Eastern Cooperative Oncology Group performance status (ECOG) \< 2. 4. Patients with normal organic function as defined for the following criteria: * Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 times the upper normal limit of the local laboratory ; * Total serum bilirubin ≤ 2.0 x ULN-LL; * Absolute neutrophil count ≥ 1,500 / mm3; * Platelet count ≥ 100,000 / mm3; * Hemoglobin ≥ 8.0 g / dl; * Serum creatinine ≤ 1.5 x ULN-LL Exclusion criteria: 1. Pregnant or nursing women, or females intending pregnancy were all prohibited 2. Patients with concurrent other malignancy or history of other malignancy treated within the past 3 years. 3. Baseline estimated glomerular filtration rate (eGFR) \< 59 ml/min/1.73 m2. 4. Alanine aminotransferase (ALT) \> 3× times ULN. 5. Eastern Cooperative Oncology Group performance status (ECOG) ≥2. 6. Patients have Diabetes mellitus. 7. Patients have current participation in other protocols with experimental drugs. 8. Patients with no ability to ingest food orally. 9. Pentoxifylline hypersensitivity. 10. Use of other nephrotoxic drugs as aminoglycosides, non-steroidal anti-inflammatory drugs and contrast media.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Head and neck squamous cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cisplatin toxicity head and neck squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pentoxifylline, cisplatin, nephrotoxixcity

Contacts and locations

Locations

  • Tanta Unuversity

    Tanta, 34518, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.